QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Secures New U.S. Patent for GelrinC Liquid Formulation
Regentis Biomaterials (NYSE American: RGNT) announced that the U.S. Patent and Trademark Office has issued the company a new patent titled “Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof,” covering a liquid, ready-to-use formulation of its lead product, GelrinC(R), as well as improved production processes that eliminate the use of organic solvents. The patent focuses on GelrinC’s liquid formulation, which is designed to simplify surgical procedures and improve patient experience by conforming precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant. Regentis said the patent provides protection for GelrinC through 2038…
